Guess which ASX 100 stock is expecting to report a 200% increase in profits

Profit guidance has been unveiled for FY 2024. Let's see what is expected.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ramsay Health Care Ltd (ASX: RHC) shares are on the slide on Monday.

At the time of writing, the ASX 100 stock is down 1.8% to $44.49.

This compares to the performance of the benchmark ASX 200 index, which is down 2.3%.

A man looking at his laptop and thinking.

Image source: Getty Images

Why is this ASX 100 stock falling?

Investors have been selling the private hospital operator's shares amid market weakness and the release of its profit guidance for FY 2024.

According to the release, subject to finalisation of the accounts and audit sign off, Ramsay is expecting to report a net profit after tax in the range of $884 million to $889 million for the 12 months.

This is up approximately 200% on the $298.1 million that the ASX 100 stock reported a year ago.

However, before you get too excited, there's a very big reason why Ramsay Health Care's profits are up significant year on year.

That reason is the company sold its 50:50 joint venture in Asia, Ramsay Sime Darby (RSD), in December 2023. This has led to it recording an after-tax cash profit on the sale of RSD of $618 million.

Profit from continuing operations

A more accurate representation of its performance in FY 2024 would be its profits from continuing operations.

The ASX 100 stock revealed that its FY 2024 net profit after tax from continuing operations is expected to be in the range of $265 million to $270 million. This compares to $278.2 million in the prior corresponding period.

The result is expected to include non-cash impairments and accelerated write-downs against the book value of underperforming assets in both Ramsay Sante and the UK region of $24.5 million after tax and minority interests.

Also included will be negative net mark to market movements in relation to interest rate swaps in Ramsay Sante's debt facilities of $13.1 million after tax.

Furthermore, as a result of the expected impairment charges and write downs, Ramsay's FY 2024 depreciation, amortisation, and impairments charge is expected to be slightly above the top end of its previously expected range of $1 billion to $1.1 billion at approximately $1.13 billion.

Finally, non-recurring items in total are expected to make a negative contribution to the result of approximately $29.5 million after tax. This compares to a positive contribution of $27.5 million in the prior corresponding period.

Excluding the impact of non-recurring items, its FY 2024 net profit after tax from continuing operations is expected to be in the range of $294 million to $299 million.

Management commented:

The Group's underlying result has been driven by improving activity trends and labour productivity, combined with a focus on sustainable performance acceleration programs and improved tariff indexation.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »

Retired couple hugging and laughing.
Healthcare Shares

A Budget announcement has put a rocket under this ASX aged care provider's shares

A shake up in the funding model will be a boost for this company.

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

What on earth's going on with Pro Medicus shares?

The quality stock is now driven heavily by expectations.

Read more »

A stressed businessman sits next to his briefcase with his head in his hands, while the ASX boards behind him show shares crashing.
52-Week Lows

CSL's collapse deepens. Why this ASX giant can't find a floor

CSL shares hit a 9-year low as new demand concerns emerge.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Prediction: CSL shares could surpass $265 in 2026

CSL shares are tumbling again on Wednesday. Here's what it'll take for the price to take a u-turn.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Why are Cochlear shares down 36% today?

The medical device manufacturer has delivered a bitter pill for shareholders.

Read more »